Tag: ABT

  • Abbott Laboratories Valuation – February 2019 $ABT

    Abbott Laboratories Valuation – February 2019 $ABT

    Abbott Laboratories does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.

  • 10 Most Overvalued Stocks of the S&P 500 – July 2018

    10 Most Overvalued Stocks of the S&P 500 – July 2018

    There are a number of great companies in the market today, but there are also a number of companies that are vastly overvalued by the market. By using the ModernGraham Valuation Model, I’ve selected the ten most overvalued companies of the S&P 500 recently reviewed by ModernGraham.

  • Abbott Laboratories Valuation – May 2018 $ABT

    Abbott Laboratories Valuation – May 2018 $ABT

    Abbott Laboratories does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.

  • Abbott Laboratories Valuation – January 2017 $ABT

    Abbott Laboratories Valuation – January 2017 $ABT

    Abbott Laboratories does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.

  • Abbott Laboratories Valuation – August 2016 $ABT

    Abbott Laboratories Valuation – August 2016 $ABT

    Abbott Laboratories does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.

  • 5 Speculative and Overvalued Companies to Avoid – March 2015

    5 Speculative and Overvalued Companies to Avoid – March 2015

    By using the ModernGraham Valuation Model, I’ve selected five of the most overvalued companies reviewed by ModernGraham. Each company has been determined to not be suitable for either the Defensive Investor or the Enterprising Investor according to the ModernGraham approach. Here’s a summary of each company’s valuation.

  • 18 Companies in the Spotlight This Week – 3/21/15

    18 Companies in the Spotlight This Week – 3/21/15

    We evaluated 18 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.

  • Abbott Laboratories Annual Valuation – 2015 $ABT

    Abbott Laboratories Annual Valuation – 2015 $ABT

    Abbott Laboratories is not suitable for the Enterprising Investor or for the Defensive Investor. The Defensive Investor is concerned by the the low current ratio, low earnings growth over the last ten years, and the high PEmg and PB ratios.

  • 26 Companies in the Spotlight This Week – 12/13/14

    26 Companies in the Spotlight This Week – 12/13/14

    We evaluated 26 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.

  • Abbott Labs Quarterly Valuation – December 2014 $ABT

    Abbott Labs Quarterly Valuation – December 2014 $ABT

    Abbott Labs qualifies for the Enterprising Investor but not for the Defensive Investor. The Defensive Investor is concerned by the low current ratio and the high PB ratio, while the Enterprising Investor is concerned by the lack of earnings growth over the last five years.